Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Alnylam Pharmaceuticals
(NQ:
ALNY
)
143.71
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 25, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
143.71
Bid (Size)
141.00 (1)
Ask (Size)
156.00 (1)
Prev. Close
143.71
Today's Range
143.71 - 143.71
52wk Range
141.97 - 218.88
Shares Outstanding
118,847,693
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
How Is The Market Feeling About Alnylam Pharmaceuticals?
April 19, 2024
Via
Benzinga
Alnylam to Webcast Conference Call Discussing First Quarter 2024 Financial Results
April 18, 2024
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Performance
YTD
-26.28%
-26.28%
1 Month
-5.44%
-5.44%
3 Month
-21.87%
-21.87%
6 Month
-7.68%
-7.68%
1 Year
-27.24%
-27.24%
More News
Read More
10 Health Care Stocks With Whale Alerts In Today's Session
April 09, 2024
Via
Benzinga
Analysts Express Confidence in Alnylam's Hypertension Drug Despite Mixed Trial Data
April 08, 2024
Via
Benzinga
Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension
April 07, 2024
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
$100 Invested In Alnylam Pharmaceuticals 15 Years Ago Would Be Worth This Much Today
April 02, 2024
Via
Benzinga
Race To Treat Alzheimer's Disease Is Heating Up Despite Eli Lilly's Setback
March 28, 2024
Via
Investor's Business Daily
Exposures
Product Safety
3 Biotech Stocks to Buy on the Dip: March 2024
March 27, 2024
Via
InvestorPlace
Alnylam to Webcast Investor Event to Discuss Results from KARDIA-2 Phase 2 Study of Zilebesiran at American College of Cardiology Scientific Session
March 20, 2024
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Earnings Scheduled For February 15, 2024
February 15, 2024
Via
Benzinga
Alnylam Pharmaceuticals's Earnings Outlook
February 14, 2024
Via
Benzinga
Here's How Much You Would Have Made Owning Alnylam Pharmaceuticals Stock In The Last 15 Years
March 18, 2024
Via
Benzinga
Billionaire’s Biotech Bets: 3 Stocks Dominating Bill Gates’ Portfolio
March 13, 2024
Via
InvestorPlace
Alnylam Launches Hereditary ATTR (hATTR) Amyloidosis Campaign to Help Shorten Time to Diagnosis for Inherited and Rapidly Progressive Disease
March 13, 2024
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Pharma Stock Roundup: Novo Nordisk's New Obesity Pill Data, Roche, AstraZeneca's Pipeline Updates
March 09, 2024
Via
Talk Markets
Exposures
Product Safety
Roche/Alnylam Blood Pressure Drug Aces In Mid-Stage Trial, Analyst Says Zilebesiran As Promising Opportunity In Addressing Global Hypertension Challenges
March 05, 2024
Via
Benzinga
Alnylam Reports Positive KARDIA-2 Topline Study Results Demonstrating Clinically Significant Blood Pressure Reductions When Zilebesiran is Added to Standard of Care Antihypertensives
March 05, 2024
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
10 Health Care Stocks Whale Activity In Today's Session
February 29, 2024
Via
Benzinga
Here's How Much $100 Invested In Alnylam Pharmaceuticals 15 Years Ago Would Be Worth Today
February 28, 2024
Via
Benzinga
Alnylam to Webcast Presentations at Upcoming March Investor Conferences
February 27, 2024
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Weight-Loss Drugs Have One Big Problem. These Drugmakers Are Taking It On.
February 23, 2024
Via
Investor's Business Daily
Goldman Sachs Downgrades Alnylam Pharmaceuticals: Here's What You Need To Know
February 16, 2024
Via
Benzinga
Why Is Alnylam Pharmaceuticals Stock Trading Lower On Thursday?
February 15, 2024
Via
Benzinga
Exposures
Product Safety
Why Alnylam Pharmaceuticals Stock Is Sinking Today
February 15, 2024
Via
The Motley Fool
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Period Activity
February 15, 2024
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.